Tuesday, July 1, 2025
CN
  • About
  • Advertise
  • Careers
  • Contact
Money Compass
  • Home
  • Financial News
  • Investment News
  • Other News
    • Bursa News
    • Government News
    • Listing Companies News
    • Oversea Financial & Investment News
  • Interviews
    • Features Interviews
    • Corporate Interviews
  • Financial & Investment Articles
  • PR Newswire
  • Login
No Result
View All Result
Money Compass
Home PR Newswire

LakeShore Biopharma Announces Leadership Transitions

by
September 4, 2024
in PR Newswire
0
LakeShore Biopharma Announces Leadership Transitions
0
SHARES
15
VIEWS
Share on FacebookShare on Twitter

GAITHERSBURG, Md., Sept. 4, 2024 /PRNewswire/ — LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) (“LakeShore Biopharma” or the “Company”), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the board of directors of the Company (the “Board”) has appointed Mr. Xu Wang as the Chief Executive Officer of the Company. He succeeds Mr. Dave Chenn and Dr. Hui Shao, who step down from the Company’s Interim Chief Executive Officer and Co-Chief Executive Officer position, respectively. Mr. Xu Wang has served as the Company’s Chief Operation Officer since June 2024, and he will no longer assume such role upon becoming the Chief Executive Officer of the Company.

The Board has also approved the appointment of Dr. Hui Shao as the Chief Business Officer of the Company, responsible for global strategic planning and global transactions, and the transition of Ms. Rachel Yu from the role of Interim Chief Financial Officer to Chief Financial Officer of the Company. Ms. Yu is also a partner at Oceanpine Capital’s healthcare practice since December 2021, where she is responsible for formulating the overall investment strategies in the healthcare sector and taking principal leadership responsibility in post-investment management of portfolio companies.

Related posts

Kavalan Blitzes IWC 2025 Taking Trio of Whisky, Distillery and Master Distiller of the Year Prizes

Kavalan Blitzes IWC 2025 Taking Trio of Whisky, Distillery and Master Distiller of the Year Prizes

July 1, 2025
From Energy Labels to Green Leadership: The ESG Rise of a Vietnamese Compliance Firm

From Energy Labels to Green Leadership: The ESG Rise of a Vietnamese Compliance Firm

July 1, 2025

In addition to these leadership transitions, the Company also announced the appointment of Dr. Hui Shao as the Vice Chairman of the Board, and the appointment of Mr. Xu Wang as a new member of the Board. The leadership transitions and board appointments became effective on September 1, 2024.

About LakeShore Biopharma 

LakeShore Biopharma, previously known as YS Biopharma, is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The Company operates in China, the United States, Singapore, and the Philippines, and is led by a management team that combines rich local expertise and global experience in the biopharmaceutical industry. For more information, please visit investor.lakeshorebio.com.

Investor Relations Contact

Robin Yang
Partner, ICR, LLC
Tel: +1 (212) 537-4035
Email: [email protected] 

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/lakeshore-biopharma-announces-leadership-transitions-302237921.html

SOURCE LakeShore Biopharma Co., Ltd.

​ 

Previous Post

BC.GAME Unveils Comprehensive Brand Upgrade, Embracing a New Era with Fresh Visuals and Enhanced User Experience

Next Post

Largest Web3 Airdrop Event: $200,000 Up for Grabs in Bybit’s TON Tournament with 14 DeFi Partners

Next Post
Largest Web3 Airdrop Event: $200,000 Up for Grabs in Bybit’s TON Tournament with 14 DeFi Partners

Largest Web3 Airdrop Event: $200,000 Up for Grabs in Bybit's TON Tournament with 14 DeFi Partners

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

BROWSE BY CATEGORIES

  • Blog
  • Bursa News
  • Corporate Interviews
  • Features Interviews
  • Financial & Investment Articles
  • Financial News
  • Government News
  • Investment News
  • Listing Companies News
  • Oversea Financial & Investment News
  • PR Newswire

BROWSE BY TOPICS

2018 League Balinese Culture Bali United Budget Travel business Champions League Chopper Bike Doctor Terawan industrial Istana Negara Malaysia Market Stories National Exam net zero emissions targets 2025 Renewable energy Visit Bali

Recent News

  • Two Malaysian Startups to Compete in USD 1M Startup World Cup Grand Finale 2025 in Silicon Valley
  • Zurich Malaysia enhances customer experience with digital tools and empathy-driven support
  • From Energy Labels to Green Leadership: The ESG Rise of a Vietnamese Compliance Firm

Category

  • Blog
  • Bursa News
  • Corporate Interviews
  • Features Interviews
  • Financial & Investment Articles
  • Financial News
  • Government News
  • Investment News
  • Listing Companies News
  • Oversea Financial & Investment News
  • PR Newswire
  • About
  • Advertise
  • Careers
  • Contact

Copyright © 2024 Money Compass Media (M) Sdn Bhd. All Rights Reserved

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Features Interviews
  • Government News
  • Financial News
  • Investment News
  • Listing Companies News
  • Corporate Interviews
  • Bursa News
  • Financial & Investment Articles
  • Oversea Financial & Investment News

Copyright © 2024 Money Compass Media (M) Sdn Bhd. All Rights Reserved